Talphera - Forum WKN: A3DWPN ISIN: US00444T2096 Kürzel: TLPH Forum: Aktien User: Summer.76

AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-10-million-private-placement-of-securities-priced-at-the-market-under-nasdaq-rules-301879430.html Upon the achievement of certain milestones accelerating the warrants' expiration date, AcelRx may receive an additional $16.3 million of gross proceeds if the common warrants are exercised in full

https://www.acelrx.com/node/14011/html ...On June 15, 2023, the Company received notice from Nasdaq confirming that the Company has cured its bid price deficiency and has regained compliance with the Minimum Bid Price Rule, and that this matter is now closed.  

Wie geht es weiter? https://www.finanznachrichten.de/nachrichten-2023-05/59189716-acelrx-zock-tipp-liefert-107-in-drei-wochen-486.htm

Die 1 vor dem Komma gab es hier ja länger nicht mehr zu sehen... 🍀

AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update https://www.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-reports-first-quarter-2023-financial Request for Emergency Use Authorization of Niyad™ submitted to the FDA in April Divestment of DSUVIA® to Alora Pharmaceuticals closed April 3, 2023 $13.4 million in cash as of March 31, 2023 ...

https://www.acelrx.com/news-releases/news-release-details/acelrx-pharmaceuticals-announces-closing-divestment-dsuviar

https://seekingalpha.com/news/3952853-acelrx-pharmaceuticals-gaap-eps-of-1_00-beats-1_51-revenue-of-0_25m-misses-4_25m • AcelRx Pharmaceuticals press release (NASDAQ:ACRX): Q4 GAAP EPS of $1.00 beats by $1.51. • Revenue of $0.25M (+1150.0% Y/Y) misses by $4.25M. • Divestment of DSUVIA to Alora Pharmaceuticals expected to close the week of April 3, 2023

https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-full-year-and-fourth-quarter-2022-financial-results-and-provides-corporate-update-301786311.html AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

Schreib ich ab den Laden... Fehlinvest. Klang so gut.

Der link dazu: https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-divestment-of-dsuvia-to-alora-pharmaceuticals-301771123.html

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals up to $116.5 million in potential sales-based milestone payments

👀

AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock https://www.prnewswire.com/news-releases/acelrx-announces-7-5-million-registered-direct-offering-of-common-stock-and-warrants-to-purchase-common-stock-301710152.html

Ist sie vom handel ausgesetzt?

Welches potential steckt hier drin? Das kursziel eines einsamen analysten scheint mir etwas fern ab. Aber gute news sollten bei der aktienzahl schon was auslösen. Was meint ihr?

Was hier los🤣